Jacopo Canzian

Milan, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Switching CDK4/6 inhibitors to overcome toxicity in HR-positive/HER2-negative advanced breast cancer.

Switching CDK4/6 inhibitors to overcome toxicity in HR-positive/HER2-negative advanced breast cancer.

Journal: Tumori

Published: July 31, 2026

Decluttering chemotherapy agents for HER2+early breast cancer: Do we still need carboplatin?

Decluttering chemotherapy agents for HER2+early breast cancer: Do we still need carboplatin?

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 20, 2026

"Neoadjuvant trastuzumab deruxtecan for high-risk HER2-positive early breast cancer: Does the evidence support its use as a new standard-of-care?"

"Neoadjuvant trastuzumab deruxtecan for high-risk HER2-positive early breast cancer: Does the evidence support its use as a new standard-of-care?"

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 15, 2026

From intravenous to subcutaneous pertuzumab/trastuzumab in breast cancer: Clinical and pharmacoeconomic drivers and barriers to switching.

From intravenous to subcutaneous pertuzumab/trastuzumab in breast cancer: Clinical and pharmacoeconomic drivers and barriers to switching.

Journal: Tumori

Published: December 15, 2025

Intratumoral microbiome in breast cancer: A hidden player in tumor development, progression and treatment response.

Intratumoral microbiome in breast cancer: A hidden player in tumor development, progression and treatment response.

Journal: Critical reviews in oncology/hematology

Published: September 23, 2025

Why Adjuvant Treatment With a CDK4/6 Inhibitor Should Be Recommended for Women With High-Risk Breast Cancer: Methodologic Considerations on Available Evidence.

Why Adjuvant Treatment With a CDK4/6 Inhibitor Should Be Recommended for Women With High-Risk Breast Cancer: Methodologic Considerations on Available Evidence.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: September 17, 2025

Avelumab combined with axitinib for patients with advanced thymoma B3 and thymic carcinoma.

Avelumab combined with axitinib for patients with advanced thymoma B3 and thymic carcinoma.

Journal: Cancer

Published: June 29, 2025

Reply to Tjalma, W.A. Comment on "Gentile et al. Superior Survival and Lower Recurrence Outcomes with Breast-Conserving Surgery Compared to Mastectomy Following Neoadjuvant Therapy in 607 Breast Cancer Patients. Cancers 2025, 17, 766".

Reply to Tjalma, W.A. Comment on "Gentile et al. Superior Survival and Lower Recurrence Outcomes with Breast-Conserving Surgery Compared to Mastectomy Following Neoadjuvant Therapy in 607 Breast Cancer Patients. Cancers 2025, 17, 766".

Journal: Cancers

Published: May 30, 2025

[18F]FDG PET/CT as a biomarker for response evaluation in neoadjuvant treatment of early breast cancer: could it become a game-changer in the scenario of the emerging (de)-escalation strategies?

[18F]FDG PET/CT as a biomarker for response evaluation in neoadjuvant treatment of early breast cancer: could it become a game-changer in the scenario of the emerging (de)-escalation strategies?

Journal: La Radiologia medica

Published: April 15, 2025

Predictors of High-Burden Residual Axillary Disease After Neoadjuvant Therapy in Breast Cancer.

Predictors of High-Burden Residual Axillary Disease After Neoadjuvant Therapy in Breast Cancer.

Journal: Cancers

Published: March 31, 2025

Heterogeneity of progression-free survival surrogacy by sex in randomized trials testing immunotherapy in non-small cell lung cancer.

Heterogeneity of progression-free survival surrogacy by sex in randomized trials testing immunotherapy in non-small cell lung cancer.

Journal: JNCI cancer spectrum

Published: March 24, 2025

Sex-Related Differences in Immunotherapy Toxicities: Insights into Dimorphic Responses.

Sex-Related Differences in Immunotherapy Toxicities: Insights into Dimorphic Responses.

Journal: Cancers

Published: February 11, 2025

Showing 1-12 of 18

Last Updated: 09/26/2026